Tamara Gassner, Christina Chittilappilly, Theo Pirich, Benjamin Neuditschko, Klaus Hackner, Judith Lind, Osman Aksoy, Uwe Graichen, Sascha Klee, Franz Herzog, Christoph Wiesner, Peter Errhalt, Martin Pecherstorfer, Klaus Podar, Sonia Vallet
BACKGROUND: Skeletal morbidity in patients with cancer has a major impact on the quality of life, and preserving bone health while improving outcomes is an important goal of modern antitumor treatment strategies. Despite their widespread use in early disease stages, the effects of immune checkpoint inhibitors (ICIs) on the skeleton are still poorly defined. Here, we initiated a comprehensive investigation of the impact of ICIs on bone health by longitudinal assessment of bone turnover markers in patients with cancer and by validation in a novel bioengineered 3D model of bone remodeling...
May 3, 2024: Journal for Immunotherapy of Cancer